2020 DIA China Annual Meeting

With the continuous improvement and integration of diagnostic technology with emerging technologies such as artificial intelligence, the R&D of antitumor drugs has transitioned from the 1.0 era of Personalized Healthcare (PHC) in 2012 to the current 2.0 era. In the 1.0 era of targeted therapy, through detection and personalized medicine (precision medicine), drugs mainly treated people with a certain type of disease. In the PHC 2.0 era, the existing biomarker detection technology, individual genetic diagnosis, AI were made full use of to accelerate the discovery of new targets, and big data to assist clinical decision-making. Thus, a new path of diagnosis and treatment has come into being, that is, to make personalized treatment plans for various tumor patients through precision medicine driven by precision detection + digital solutions. With the upgrade of the diagnosis and treatment ecosystem, it’s increasingly urgent to more effectively use new technologies to accelerate the development of new antitumor drugs, improve the accuracy of early diagnosis, and enhance the availability of tumor drugs to meet the medication needs of cancer patients and improve their quality of life. We invite experts to share ideas and discuss from the perspectives of regulations, diagnosis, treatment, and drug availability.